Clinical Efficacy or Tildrakizumab in Patients with Chronic Plaque Psoriasis Over 2 Years of Treatment: Results from Long-Term Extensions to 2 Phase 3 Clinical Studies

Main Article Content

Kim Papp
Kristian Reich
Andrew Blauvelt
Diamant Thaci
Rodney Sinclair
Stephen K Tyring
Nicole Cichanowitz
Stuart Green
Qing Li
Carmen La Rosa

Keywords

psoriasis, tildrakizumab, clinical trial

Abstract

Abstract not available.

 

Study supported by Merck & Co., Inc.

Article Sidebar

Poster PDF
Published
Feb 23, 2018
DOI https://doi.org/10.25251/skin.2.supp.4

Article Details

How to Cite
Papp, K., Reich, K., Blauvelt, A., Thaci, D., Sinclair, R., Tyring, S. K., Cichanowitz, N., Green, S., Li, Q., & La Rosa, C. (2018). Clinical Efficacy or Tildrakizumab in Patients with Chronic Plaque Psoriasis Over 2 Years of Treatment: Results from Long-Term Extensions to 2 Phase 3 Clinical Studies. SKIN The Journal of Cutaneous Medicine, 2(S1), S4. https://doi.org/10.25251/skin.2.supp.4
Issue
Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Section
Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors transfer copyright to the publisher as part of the journal publishing agreement.

All reprints are subject to the reprint policy.